Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03261206
Other study ID # RP1610
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date November 20, 2017
Est. completion date June 2026

Study information

Verified date May 2024
Source Alimentiv Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.


Description:

Aminosalicylate (5-ASA) agents have proven effective for inducing and maintaining remission in mild to moderate ulcerative colitis (UC) and thus are commonly used as first-line agents for patients with Crohn's disease (CD) in remission. However, there is uncertainty regarding their effectiveness for CD. In this open-label, randomized study, participants with CD in remission will be allocated to either continue their 5-ASA therapy or withdraw their 5-ASA. The purpose is to investigate if withdrawal of 5-ASA therapy is not unacceptably less effective than continuing on 5-ASA in maintaining CD remission over a 24 month period.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 334
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Documented diagnosis of CD at least 3 months prior to enrollment - Taking any brand or dosage of an oral aminosalicylate for at least 6 months - Subject-confirmed compliance with current aminosalicylate therapy (taking at least 75% of prescribed doses) - CD currently in clinical remission - Able to participate fully in all aspects of the clinical trial - Written informed consent obtained and documented Exclusion Criteria: - A current diagnosis of UC, indeterminate colitis, microscopic colitis, or diverticular disease-associated colitis - A diagnosis of short-bowel syndrome - Active perianal disease - Active fistulizing disease - A flare of CD within 3 months prior to enrollment requiring initiation/escalation of medical therapy or surgery - Use of systemic corticosteroids for CD (2 continuous weeks or more) within 3 months prior to enrollment - Any major resective bowel surgery for CD (ileal resection, ileocecal resection, proctocolectomy, colectomy, enterectomy, ostomy formation and repair, anastomosis/reanastomosis) within 6 months prior to enrollment - Unwillingness to stop taking aminosalicylates for the duration of the trial - Untreated bile salt malabsorption that, in the opinion of the investigator, may interfere with accurate study HBI assessment - Serious underlying disease other than CD that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study - History of active alcohol or drug abuse that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures - Currently participating in another interventional trial, or previous participation within the last 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
5-ASA Withdrawal
Withdrawal of 5-ASA therapy

Locations

Country Name City State
Canada University of Calgary Calgary Alberta
Canada Dr. Jesse Siffledeen Professional Medical Corporation Edmonton Alberta
Canada University of Alberta Edmonton Alberta
Canada London Health Sciences Centre - University Hospital London Ontario
Canada McGill University Healthcare Montréal Quebec
Canada Scott Shulman Medical Professional Corporation North Bay Ontario
Canada Taunton Surgical Center Oshawa Ontario
Canada Mount Sinai Hospital Toronto Ontario
Canada (G.I.R.I.) GI Research Institute Vancouver British Columbia
Canada Discovery Clinical Services Ltd. Victoria British Columbia
Canada Dr. O. Tarabain Medicine Professional Corporation Windsor Ontario
Canada University of Manitoba - Health Sciences Centre Winnipeg Manitoba
Italy IRCCA De Bellis Castellana Grotte Via Turi
Italy Luigi Vanvitelli of Campania Catania
Italy Intituto Clinico Humanitas Milano
Italy Azienda Ospedale-Universita Padova Padova
Italy Campus Bio-Medico University of Rome Roma
Italy UOC Gastroenterologic UOS Malattie Infiammatorie Intestinali, Ospedali Roma Rome
Italy IRCCS Policlinico San Donato San Donato Milanese Milan Italy
Ukraine BYK - Kyiv Kyiv
Ukraine Danylo Halytsky Lviv National Medical University Lviv
Ukraine Odesa Regional Clinical Hospital Odesa
Ukraine Ternopil University Hospital Ternopil
Ukraine Vinnytsia Nation Medical University N.I. Pirogov Vinnytsia
United Kingdom Barnsley Hospital NHS Trust Barnsley Yorkshire
United Kingdom Basildon and Thurrock University Hospitals NHS Foundation Trust Basildon Essex
United Kingdom Bedford Hospital NHS Trust Bedford
United Kingdom Royal Blackburn Hospital Blackburn Lancashire
United Kingdom Northern Care Alliance NHS Group - Fairfield General Hospital Bury
United Kingdom West Suffolk Hospital Bury St Edmunds
United Kingdom Darlington Memorial Hospital Darlington Durham
United Kingdom Royal Devon and Exeter NHS Foundation Trust Exeter
United Kingdom St. Marks Hospital Harrow Middlesex
United Kingdom Guy's and St. Thomas' Hospitals NHS Trust London
United Kingdom Royal Free Hospital London
United Kingdom Luton and Dustable Hospital Foundation Trust Luton
United Kingdom Nottingham University Hospitals NHS Trust and University of Nottingham Nottingham
United Kingdom Royal Berkshire NHS Foundation Trust Reading
United Kingdom Salford Ryal NHS Foundation Trust Salford
United Kingdom Airedale NHS Foundation Trust Steeton
United Kingdom Sherwood Forest Hospitals NHS Foundation Trust - Kings Mill Hospital Sutton In Ashfield Nottinghamshire
United Kingdom Warrington and Halton Hospitals NHS Foundation Trust Warrington Cheshire

Sponsors (2)

Lead Sponsor Collaborator
Alimentiv Inc. Academic Medical Organization of Southwestern Ontario

Countries where clinical trial is conducted

Canada,  Italy,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary CD-related complications at 2 years CD-related complications include either a CD-related or CD treatment-related surgery, hospitalization, or other complication 24 months
Secondary CD-related complications at 1 year CD-related complications include either a CD-related or CD treatment-related surgery, hospitalization, or other complication 12 months
Secondary CD-related or CD-treatment related surgeries at 1 year 12 months
Secondary CD-related or CD-treatment related surgeries at 2 years 24 months
Secondary CD-related or CD-treatment related hospitalizations at 1 year 12 months
Secondary CD-related or CD-treatment related hospitalizations at 2 years 24 months
Secondary Other CD-related or CD-treatment related complications at 1 year Other complication excludes surgeries or hospitalizations 12 months
Secondary Other CD-related or CD-treatment related complications at 2 years Other complication excludes surgeries or hospitalizations 24 months
Secondary Proportion of patients who require the use of systemic corticosteroids for treatment of CD flares at 1 year 12 months
Secondary Proportion of patients who require the use of systemic corticosteroids for treatment of CD flares at 2 years 24 months
Secondary Time to first CD-related complication CD-related complications include either a CD-related or CD treatment-related surgery, hospitalization, or other complication up to 24 months
Secondary Change in disease activity at 6 months Disease activity assessed by HBI score 6 months
Secondary Change in disease activity at 12 months Disease activity assessed by HBI score 12 months
Secondary Change in disease activity at 24 months Disease activity assessed by HBI score 24 months
Secondary Change in self-assessed quality of life at 6 months Quality of life assessed with the Crohn's and Ulcerative Colitis Questionnaire 32-item Base line and 6 months
Secondary Change in self-assessed quality of life at 1 year Quality of life assessed with the Crohn's and Ulcerative Colitis Questionnaire 32-item Base line and 12 months
Secondary Change in self-assessed quality of life at 2 years Quality of life assessed with the Crohn's and Ulcerative Colitis Questionnaire 32-item Base line and 24 months
Secondary Change in C-reactive protein concentration at 6 months Base line and 6 months
Secondary Change in C-reactive protein concentration at 1 year Base line and 12 months
Secondary Change in C-reactive protein concentration at 2 years Base line and 24 months
Secondary Change in fecal calprotectin concentration at 1 year Base line and 12 months
Secondary Change in fecal calprotectin concentration at 2 years Base line and 24 months
Secondary Change in CD-related drug treatment costs at 2 years Estimated drug treatment costs before and after enrollment 12 months prior to enrollment and 24 months after enrollment
Secondary Change in CD-related and total healthcare costs at 2 years Estimated costs before and after enrollment 12 months prior to enrollment and 24 months after enrollment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05294107 - Intestinal Organoids N/A
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Recruiting NCT05906576 - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Phase 4
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2